LoginSignup
CYB

Helus Pharma Inc.

Stock
Stock
ISIN: CA4234921076
Ticker: CYBN
CA4234921076
CYBN

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Helus Pharma Inc. is $851.37M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Helus Pharma Inc.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.865. EPS indicates the company's profitability on a per-share basis.
Currently, 11 analysts cover Helus Pharma Inc.'s stock, with a consensus target price of $56.96. Analyst ratings provide insights into the stock's expected performance.
Helus Pharma Inc.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$230.69M. EBITDA measures the company's overall financial performance.
Helus Pharma Inc. has a free cash flow of -$196.62M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Helus Pharma Inc. employs approximately 100 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Helus Pharma Inc. is 49.04M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$851.37M
EPS (TTM) 
-$5.865
Free Float 
49.04M
EBITDA (TTM) 
-$230.69M
Free Cashflow (TTM) 
-$196.62M

Pricing

52W span
$3.798$14.92

Analyst Ratings

The price target is $56.96 and the stock is covered by 11 analysts.

Buy

11

Hold

0

Sell

0

Information

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Employees
100
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

ISIN
CA4234921076
Primary Ticker
CYBN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin